Multiple sclerosis (MS,) is a disease in which the fatty myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and scarring as well as a broad spectrum of signs and symptoms. Disease onset usually occurs in young adults, and it is more common in females. It has a prevalence that ranges between 2 and 150 per 100,000.
|
[News]
Gut Bacteria Affect Multiple Sclerosis
Biologists at the California Institute of Technology (Caltech) have demonstrated a connection between multiple sclerosis (MS) -- an autoimmune disorder that affects the brain and spinal cord -- and gut bacteria.
|
|
[News]
Multiple Sclerosis Successfully Treated Yet Again With Adult Stem Cells
After participating in a small clinical trial at Northwestern University, Edwin McClure seems to have recovered from multiple sclerosis (MS). Conducted on 21 participants and led by Dr. Richard Burt, the clinical trial involved treating the MS patients with their own adult stem cells. The only drawback of the study, however, was the use of chemotherapy to destroy each patient's immune system prior to the adult stem cell therapy. Nevertheless, patients such as Mr. McClure have shown dramatic improvement.
|
|
[News]
Multiple Sclerosis Linked to Different Area of Brain
Radiology researchers at The University of Texas Health Science Center at Houston (UTHealth) have found evidence that multiple sclerosis affects an area of the brain that controls cognitive, sensory and motor functioning apart from the disabling damage caused by the disease's visible lesions.
|
|
[News]
Further Evidence Links Epstein-Barr Virus and Risk of Multiple Sclerosis
Researchers from the Harvard School of Public Health, Walter Reed Army Institute of Research, and a team of collaborators have observed for the first time that the risk of multiple sclerosis (MS) increases by many folds following infection with the Epstein-Barr virus (EBV). This finding implicates EBV as a contributory cause to multiple sclerosis.
|
|
[News]
Promising Therapy for Relapsing Multiple Sclerosis
An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.
|
|
[News]
Statins May Slow Progression of Multiple Sclerosis
A UCSF-led study examining the impact of statins on the progression of multiple sclerosis found a lower incidence of new brain lesions in patients taking the cholesterol-lowering drug in the early stages of the disease as compared to a placebo.
|
|
[News]
Compound Effectively Halts Progression of MS in Animal Model
Scientists from the Florida campus of The Scripps Research Institute have developed the first of a new class of highly selective compounds that effectively suppresses the severity of multiple sclerosis in animal models. The new compound could provide new and potentially more effective therapeutic approaches to multiple sclerosis and other autoimmune diseases that affect patients worldwide.
|
|
[News]
Starving Inflammatory Immune Cells Slows Damage Caused by Multiple Sclerosis
ScienceDaily (Sep. 2, 2011) In a paper published in the journal Scientific Reports, a pair of researchers at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences report that inhibiting the ability of immune cells to use fatty acids as fuel measurably slows disease progression in a mouse model of multiple sclerosis (MS).
|
|
[News]
Multiple Sclerosis Research Doubles Number of Genes Associated With the Disease, Increasing the Number to Over 50
Dr. John Rioux, researcher at the Montreal Heart Institute, Associate Professor of Medicine at the Universit¨¦ de Montr¨¦al and original co-founder of the International Multiple Sclerosis Genetics Consortium is one of the scientists who have identified 29 new genetic variants linked to multiple sclerosis, providing key insights into the biology of a very debilitating neurological disease. Many of the genes implicated in the study are relevant to the immune system, shedding light onto the immunological pathways that underlie the development of multiple sclerosis.
|
|
[News]
Blocking Crucial Molecule Could Help Treat Multiple Sclerosis
Reporting in Nature Immunology, Jefferson neuroscientists have identified a driving force behind autoimmune diseases such as multiple sclerosis (MS), and suggest that blocking this cell-signaling molecule is the first step in developing new treatments to eradicate these diseases.
|
|
[News]
Vascular Multiple Sclerosis Hypothesis and Treatment Questioned
Two important new studies challenge the controversial hypothesis that venous congestion -- chronic cerebrospinal venous insufficiency (CCSVI) -- contributes to the development of multiple sclerosis (MS). This theory has resulted in many MS patients receiving experimental endovascular angioplasty, a treatment for MS unproven by clinical trials.
|
|
[News]
New Target for Treatment of Multiple Sclerosis
The immune system recognizes and neutralizes or destroys toxins and foreign pathogens that have gained access to the body. Autoimmune diseases result when the system attacks the body's own tissues instead. One of the most common examples is multiple sclerosis (MS). MS is a serious condition in which nerve-cell projections, or axons, in the brain and the spinal cord are destroyed as a result of misdirected inflammatory reactions. It is often characterized by an unpredictable course, with periods of remission being interrupted by episodes of relapse.
|
|
[News]
Mindfulness Meditation May Ease Fatigue, Depression in Multiple Sclerosis
Learning mindfulness meditation may help people who have multiple sclerosis (MS) with the fatigue, depression and other life challenges that commonly accompany the disease, according to a study published in the September 28, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.
|
|
[News]
MS change With The Seasons
A new US study that compared brain scans of people with multiple sclerosis to weather data over a two year period found that disease activity varied with the seasons, with spring and summer months showing predominantly the highest rates of activity, but with increased temperature and solar activity also showing a strong link. The researchers said designers of drug trials that use brain scans to measure results should also consider the possible influence of seasonal effects.
|
|
[News]
Radiation Therapy Improves Painful Condition Associated With Multiple Sclerosis
Stereotactic radiation is an effective, long-term treatment for trigeminal neuralgia: a painful condition that occurs with increased frequency in patients with multiple sclerosis (MS). Radiation is noninvasive and has less negative side effects than other treatments, according to the longest follow-up in a study of its kind to be presented Oct. 31, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
|
|
[Research & Advances]
Men And Women Equally Transmit Genetic Risk Of Multiple Sclerosis To Their
Men and women with multiple sclerosis (MS) equally transmit the genetic risk of the disease to their children, according to a study published June 27, 2007, in the online edition of Neurology®, the medical journal of the American Academy of Neurology. The research contradicts the results of a recent study, which found affected fathers were more likely than affected mothers to transmit the risk of developing MS to their children.
|
|
[Research & Advances]
Multiple Sclerosis Onset: Could Mycobacteria Play a Role?
A non-pathogenic bacterium is capable to trigger an autoimmune disease similar to the multiple sclerosis in the mouse, the model animal which helps to explain how human diseases work. This is what a group of researchers from the Catholic University of Rome, led by Francesco Ria (Institute of General Pathology) and Giovanni Delogu (Institute of Microbiology), have explained for the first time in a recently published article on the Journal of Immunology.
|
|
|
|
|
[
[
[
[
